Donanemab, Eli Lilly’s Early Alzheimer’s Disease Treatment Approved By FDA July 02, 2024, 08:35:35 PM Donanemab, Eli Lilly’s Early Alzheimer’s Disease Treatment Approved By FDA[html]Donanemab is a monoclonal antibody that the U.S. Food and Drug Administration (FDA) approved on Tuesday with the goal of slowing the progression of early-stage symptomatic Alzheimer's disease.[/html]Source: Donanemab, Eli Lilly’s Early Alzheimer’s Disease Treatment Approved By FDA (http://ht**://www.oann.c**/newsroom/donanemab-eli-lillys-early-alzheimers-disease-treatment-approved-by-fda/) Quote Selected